Filling a gap so biotech startups can advance to the next level

By Samantha Black, PhD, ScienceBoard editor in chief

October 26, 2021 -- In the biotechnology industry, there is a need for capital among companies that are already commercial and have products with demonstrated success but that might not yet be profitable. BroadOak Capital fills the gap for biotech companies between venture capital (for startups) and private equity (for already profitable companies), according to BroadOak partner Bill Snider in an exclusive interview with Editor-in-Chief Samantha Black, PhD.

BroadOak Capital was founded in 2006 with the goal of staying in the biotechnology business while focusing on the research and diagnostics tools and services in the space. Research tools encompass everything in a lab, including low-tech instruments such as hoods and freezers to expensive analytical equipment and reagents, according to Snider. These tools are not regulated by the U.S. Food and Drug Administration (FDA) but are used to create products that are regulated by the FDA.

The company is also interested in investing in the pharmaceutical services industry, which could include good laboratory practice testing services, contract research organization services, or clinical trial and trial recruitment services.

"The products that might become a drug are innovative, but oftentimes they require an innovative tool that cracked an old problem that people were having a hard time getting around," Snider said.

Video loading ...

Over the last decade, BroadOak has made over 50 growth capital investments within the biotech space. The company continues to be focused on investing in research tools and services within the cell and gene therapy, single-cell analysis, and synthetic biology spheres.

When asked what advice he has for scientific entrepreneurs, Snider said, "View the financial community as a collaborator. When you are working on a hard problem, you want to bring on people with multiple expertise and diverse ways of thinking ... If you view them as a collaborator rather than someone who doesn't see the world the way you do, you end up with a mutually beneficial experience."

Do you have a unique perspective on your research related to biotech finance? Contact the editor today to learn more.


Copyright © 2021
To access all The ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
I have read and agree to the privacy policy and terms of service and wish to opt-in for

Already have an account? Sign in here